Clinical practice guidelines on frontline and relapsed refractory management published
The TiNKS trial combines a standard chemotherapy regimen with an off-the-shelf natural killer (NK) cell product developed to function in the solid tumor microenvironment. The multi-site study completed its initial safety phase in 2024 and is now expanding to evaluate efficacy in select histologies. Both guidelines call for additional research on treating this patient population for ALL, including clinical trials directly […]
Clinical practice guidelines on frontline and relapsed refractory management published Read More »